home / stock / matn / matn quote
Last: | $0.26 |
---|---|
Change Percent: | 8.33% |
Open: | $0.235 |
Close: | $0.26 |
High: | $0.27 |
Low: | $0.221 |
Volume: | 108,017 |
Last Trade Date Time: | 03/29/2021 04:55:56 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.26 | $0.235 | $0.26 | $0.27 | $0.221 | 108,017 | 03-29-2021 |
$0.24 | $0.25 | $0.24 | $0.268 | $0.2066 | 115,877 | 03-26-2021 |
$0.25 | $0.23 | $0.25 | $0.25 | $0.2175 | 174,565 | 03-25-2021 |
$0.25 | $0.25 | $0.25 | $0.26 | $0.2149 | 270,015 | 03-24-2021 |
$0.249 | $0.268 | $0.249 | $0.28 | $0.217 | 179,575 | 03-23-2021 |
$0.27 | $0.2479 | $0.27 | $0.28 | $0.217 | 267,309 | 03-22-2021 |
$0.2425 | $0.29 | $0.2425 | $0.29 | $0.19 | 540,813 | 03-19-2021 |
$0.275 | $0.278 | $0.275 | $0.29 | $0.267 | 137,651 | 03-18-2021 |
$0.278 | $0.285 | $0.278 | $0.285 | $0.267 | 41,112 | 03-17-2021 |
$0.28 | $0.2749 | $0.28 | $0.28 | $0.261 | 105,481 | 03-16-2021 |
$0.2747 | $0.28 | $0.2747 | $0.295 | $0.24 | 365,712 | 03-15-2021 |
$0.2388 | $0.255 | $0.2388 | $0.2598 | $0.2387 | 126,941 | 03-12-2021 |
$0.2598 | $0.2363 | $0.2598 | $0.26 | $0.2363 | 111,910 | 03-11-2021 |
$0.24 | $0.23 | $0.24 | $0.2629 | $0.2225 | 199,612 | 03-10-2021 |
$0.2248 | $0.237 | $0.2248 | $0.242 | $0.219 | 147,718 | 03-09-2021 |
$0.237 | $0.24 | $0.237 | $0.26 | $0.225 | 220,288 | 03-08-2021 |
$0.2275 | $0.22 | $0.2275 | $0.2298 | $0.205 | 168,670 | 03-05-2021 |
$0.22 | $0.213 | $0.22 | $0.225 | $0.191 | 442,658 | 03-04-2021 |
$0.2151 | $0.22 | $0.2151 | $0.24 | $0.2 | 631,975 | 03-03-2021 |
$0.218 | $0.259 | $0.218 | $0.259 | $0.2042 | 594,609 | 03-02-2021 |
News, Short Squeeze, Breakout and More Instantly...
Mateon Therapeutics Inc. Company Name:
MATN Stock Symbol:
OTCMKTS Market:
Mateon Therapeutics Inc. Website:
AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phase 1b clinical trial of a patented OT-101/IL-2 combination. This phase 1b clinical trial w...
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon”) (OTCQB:MATN) announced today that it has completed t...
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, and Windlas Biotech Pvt. Ltd. (Windlas), a leading I...